and the indemnity of the drug manufacturer when lawsuits of the import vaccine of a new influenza due to the side reaction damage occur. It corresponds according to Ministry of Health, Labour and Welfare by receiving the request of the drug manufacturer of the discharge concerning the side reaction as the condition of the vaccine sales. The development of legal systems is necessary to connect such an agreement with the drug manufacturer, and the legislation preparation for the extraordinary Diet session submission will become full-scale in the government in the future. 【 Kenji Shimizu ]
The vaccination subject in the fiscal year that Ministry of Health, Labour and Welfare assumes is about 54 million people. As for the vaccines that can be produced domestically, the deficiency is scheduled to be covered by the import in 30 million the greatest people when one person is assumed to be inoculation twice.
Two companies (Glaxo SmithKline of the drug manufacturer major (Britain) and Novartis (Switzerland)) and it negotiates with the import. It is requested that the discharge be included in the agreement for which country, and according to Ministry of Health, Labour and Welfare, in both companies, the pledge is a difficult situation and Iu as long as it doesn't agree.
There is salvation system that a constant forehead is paid from the contribution of the drug manufacturer for the side reaction of the medicine regardless of the presence of drug manufacturer and doctors' faults in case of Japan. However, it is also possible that the aggrieved party causes the damages suit with the ingluvies food. When lawsuits come one after another in each country, the drug manufacturer is requesting the discharge because there is a risk that management is pressed.
However, the country's connecting the agreement that doesn't cap the amount has the constraint on Public Finance Law, and the Ministry of Health, Labour and Welfare medicine food bureau assumes, "The law that becomes the rationale of the spending is necessary". The government starts the work of the stuff for the extraordinary Diet session.
There is a system to the drug manufacturer etc. that cannot file suit in the United States etc. according to Ministry of Health, Labour and Welfare when the aggrieved party receives a public compensation. The introduction in Japan is not easy though a new such case discharge is unnecessary relate to the right to receive the litigation secured in the constitution.
- Language new influenza vaccine
Adjuvant of the nonuse enters in Japan for the vaccine that Japan is discussing the import, and the technology of the cell culture that has not been established in Japan is used. Inoculation starts in the end of December through the approval of the pharmaceutical Affiars Law if it is early. The home manufacture is manufactured by the method of using the egg similar to for conventional seasonality, and is an outlook of the inoculation start in the end of October.
http://mainichi.jp/select/biz/news/20090921k0000m040118000c.html
Japan is good country!
http://japan-power.net/
PLEASE come here!
The vaccination subject in the fiscal year that Ministry of Health, Labour and Welfare assumes is about 54 million people. As for the vaccines that can be produced domestically, the deficiency is scheduled to be covered by the import in 30 million the greatest people when one person is assumed to be inoculation twice.
Two companies (Glaxo SmithKline of the drug manufacturer major (Britain) and Novartis (Switzerland)) and it negotiates with the import. It is requested that the discharge be included in the agreement for which country, and according to Ministry of Health, Labour and Welfare, in both companies, the pledge is a difficult situation and Iu as long as it doesn't agree.
There is salvation system that a constant forehead is paid from the contribution of the drug manufacturer for the side reaction of the medicine regardless of the presence of drug manufacturer and doctors' faults in case of Japan. However, it is also possible that the aggrieved party causes the damages suit with the ingluvies food. When lawsuits come one after another in each country, the drug manufacturer is requesting the discharge because there is a risk that management is pressed.
However, the country's connecting the agreement that doesn't cap the amount has the constraint on Public Finance Law, and the Ministry of Health, Labour and Welfare medicine food bureau assumes, "The law that becomes the rationale of the spending is necessary". The government starts the work of the stuff for the extraordinary Diet session.
There is a system to the drug manufacturer etc. that cannot file suit in the United States etc. according to Ministry of Health, Labour and Welfare when the aggrieved party receives a public compensation. The introduction in Japan is not easy though a new such case discharge is unnecessary relate to the right to receive the litigation secured in the constitution.
- Language new influenza vaccine
Adjuvant of the nonuse enters in Japan for the vaccine that Japan is discussing the import, and the technology of the cell culture that has not been established in Japan is used. Inoculation starts in the end of December through the approval of the pharmaceutical Affiars Law if it is early. The home manufacture is manufactured by the method of using the egg similar to for conventional seasonality, and is an outlook of the inoculation start in the end of October.
http://mainichi.jp/select/biz/news/20090921k0000m040118000c.html
Japan is good country!
http://japan-power.net/
PLEASE come here!
はてなに追加
MyYahoo!に追加
del.icio.usに追加
livedoorClipに追加
コメントする